Actinium Pharmaceuticals develops targeted radiotherapies for cancer using its Antibody Radiation Conjugates platform and alpha-emitting radioisotopes. Company updates commonly focus on ATNM-400, an Actinium-225 antibody radioconjugate studied in solid tumor models including prostate, lung, and breast cancer, and Actimab-A, or lintuzumab-Ac225, an Actinium-225 therapy targeting CD33 in acute myeloid leukemia.
Additional announcements describe radiochemistry work such as chelator-to-antibody ratio optimization, preclinical data presented at oncology and nuclear medicine meetings, and the company's broader radiotherapy platform across solid tumors, hematologic malignancies, and conditioning for cellular therapies.
Summary not available.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced several key senior leadership appointments aimed at advancing its growth strategy. Arun Swaminathan, Ph.D., has been appointed as Chief Business and Commercial Officer, while Paul Diamond, Ph.D., joins as Vice President, Patent and Legal Counsel. Avinash Desai, M.D., has been promoted to Chief Medical Officer. These leaders together bring over 50 years of experience in biopharmaceuticals, enhancing Actinium's focus on its pipeline, particularly the recently completed Phase 3 SIERRA trial for Iomab-B.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced its participation in four upcoming investor conferences, highlighting its pivotal Phase 3 trial for Iomab-B and upcoming milestones from its targeted radiotherapy pipeline. The conferences are scheduled from September 27 to October 13, 2021. CEO Sandesh Seth emphasized the strong momentum as the company approaches significant data updates in the fourth quarter. Actinium specializes in targeted radiotherapies aimed at treating patients with unmet needs, focusing on improving outcomes through innovative therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has completed enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B, aimed at treating patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial, involving 150 patients across 24 centers in the U.S. and Canada, assesses the efficacy of Iomab-B in providing Bone Marrow Transplant (BMT) access. Actinium plans to present data updates in Q4 2021 and topline results in mid-2022 to support a Biologics License Application (BLA) for Iomab-B.
Actinium Pharmaceuticals (NYSE: ATNM) announced its inclusion in the Russell Microcap® Index effective June 28, 2021. This membership, determined by market-cap rankings, will last for one year and grants Actinium access to associated growth and value style indexes. The Russell indexes are critical benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. As a clinical-stage biopharmaceutical company, Actinium focuses on developing innovative therapies, notably its lead candidate I-131 apamistamab, which is under study for conditioning before bone marrow transplants.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the enhancement of its intellectual property portfolio for its lead candidate, Iomab-B, with patents granted in the EU and Japan. These patents, covering the composition and administration methods of Iomab-B, are expected to be valid through 2036 and 2037. Actinium aims to leverage its patents for aggressive development in targeted conditioning, particularly for bone marrow transplants and cell therapies. The company holds multiple patents globally and enjoys orphan drug designation for Iomab-B, potentially providing market exclusivity.
Actinium Pharmaceuticals (NYSE: ATNM) presented promising data from its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 SNMMI Annual Meeting. Iomab-B, a radiotherapy targeting CD45, aims to enable potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial showed a remarkable 100% BMT and engraftment rate in the Iomab-B group, while only 18% in the control arm. With 75% patient enrollment completed, the results highlight Iomab-B's potential to transform treatment outcomes in this challenging patient population.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented safety data from the Phase 3 SIERRA trial of Iomab-B for relapsed or refractory Acute Myeloid Leukemia at the 2021 SNMMI Annual Meeting. The study involved 113 patients, demonstrating lower rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Iomab-B's targeted delivery system aims to minimize side effects while preparing patients for bone marrow transplants. With 75% enrollment complete, Actinium anticipates further data presentations in the future.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced acceptance of three abstracts from its pivotal Phase 3 SIERRA trial for Iomab-B at the SNMMI 2021 Annual Meeting, scheduled for June 11-14. Iomab-B targets conditioning prior to bone marrow transplantation for patients aged 55 and over with relapsed or refractory acute myeloid leukemia. The trial reports a 25%, 50%, and 75% enrollment, showcasing Iomab-B's potential as a best-in-class treatment with low transplant-related mortality. The findings emphasize the significance of Iomab-B in improving BMT outcomes.
Actinium Pharmaceuticals (NYSE: ATNM) will present its Iomab-ACT program at the Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. Iomab-ACT is a lower-dose radiation treatment aimed at achieving lymphodepletion before CAR-T therapies and gene therapies. The company collaborates with Memorial Sloan Kettering Cancer Center for a pioneering trial targeting CD19 CAR T-cell therapy, and with UC Davis for anti-HIV stem cell gene therapy. Actinium continues to advance its clinical pipeline focusing on improving patient outcomes in hematologic malignancies.